Single-dose high dose-rate brachytherapy is safe and effective for low-risk prostate cancer, delegates to ESTRO 38, this week’s annual meeting of the European Society for Radiotherapy and Oncology in Milan, were assured.
Hannah Tharmalingam, from the Mount Vernon Cancer Center in Northwood, England, and colleagues treated 441 men with D’Amico classified low-risk (44 patients), intermediate-risk (285 patients), and high-risk (112 patients) prostate cancer with HDR monotherapy to a dose of 19 Gy delivered in a single treatment exposure. A total of 166 patients received androgen deprivation therapy.
Patients were followed for a median of 26 months. The researchers found two-year biochemical progression-free survival (bPFS) rates of 100, 95, and 92 percent for low-risk, intermediate-risk, and high-risk patients, respectively, and 94 percent for all patients. The three-year bPFS rates were 100, 86, and 75 percent for low-risk, intermediate-risk, and high-risk, respectively, and 88 percent overall.
In 25 of 27 biochemical failures, the sites of relapse were radiologically identified; 15 had a local prostate recurrence. There were no serious side effects noted at the time of the treatment; however, two men later developed urethral strictures that required surgery and two men developed rectal fistulae requiring colostomy.
“This type of treatment offers an attractive alternative to surgery or other forms of radiotherapy as it has a comparatively low risk of side effects,” Tharmalingam said in a statement
REFERENCE: Abstract no: OC-0633, “Single dose high dose-rate (HDR) brachytherapy as monotherapy for localised prostate cancer”. ESTRO 38 https://user-swndwmf.cld.bz/ESTRO-38-Abstract-book